XBIO Research | Milton Maxwell

XBIO

Xenetic Biosciences, Inc.

2.0700

-0.2700-11.5%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

4.74M

P/E (TTM)

Basic EPS (TTM)

-2.04

Dividend Yield

Recent Filings

8-K

2025 results: narrower loss, DNase advances

3/13/26Mar 13, 2026

Xenetic Biosciences reported 2025 results on March 13, 2026, posting a $2.7 million net loss while royalty revenue rose 19% to $3.0 million from Takeda sublicense. DNase I program advanced with preclinical data, ongoing PDAC studies, and IND progress; cash hit $7.9 million after $4.0 million offering. Pursuing strategic alternatives. Board eyes value-maximizing paths.

10-K

FY2025 results

3/12/26Mar 12, 2026

Xenetic Biosciences posted FY2025 royalty revenue of $3.0M, up 19% y/y from $2.5M, fueled by PolyXen sublicense sales to Takeda—its sole topline source amid zero product revenue. R&D spend eased 7% to $3.1M despite Q4 ramp in DNase preclinicals with Scripps ($0.3M added), PeriNess trials, and UVA work, after 2024's $0.7M legacy asset writedown; G&A fell 20% sans CEO severance. Cash swelled to $7.9M post-$4M October offering, funding runway past 12 months while eyeing DNase clinic entry. Strategic review hunts sale or merger. DNase falters if trials flop.

8-K

Annual meeting adjourned again

1/9/26Jan 9, 2026

Xenetic Biosciences adjourned its 2025 Annual Meeting twice—first from December 11, 2025, to January 8, 2026, then again on that date—due to insufficient quorum. No business conducted. The board sought extra time for proxy solicitation. Reconvened date pending.

8-K

Annual meeting adjourned

12/11/25Dec 11, 2025

Xenetic Biosciences adjourned its 2025 Annual Meeting on December 11 after failing to secure a quorum, reconvening virtually on January 8, 2026, to solicit more proxies for the board. No business was conducted. Quorum shortfall signals low turnout.

8-K

Q3 loss $0.5M, revenue jumps

11/13/25Nov 13, 2025

Xenetic Biosciences reported Q3 2025 net loss of $0.5 million, with revenue up 67.2% to $1.0 million from Takeda royalties while R&D expenses doubled to $0.8 million on DNase manufacturing and preclinical work. Cash stood at $4.1 million, bolstered by $3.9 million net proceeds from an October offering. DNase advances toward Phase 1 for pancreatic cancer. Strategic review ongoing.

About

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

CEO

Mr. James F. Parslow

IPO

6/30/2016

Website

https://www.xeneticbio.com

Employees

Sector

Healthcare

Industry

Biotechnology